Biovest International
Biovest International is a biotechnology company originally focused on the commercialization of personalized immunotherapies, including an active personalized cancer vaccine candidate evaluated in collaboration with a national cancer institute. The company also developed cell culture and bioreactor technologies and later spun off its instrument and contract manufacturing operations into a dedicated subsidiary that supplies automated single-use perfusion bioreactors and custom mammalian cell and protein manufacturing services to global diagnostic, therapeutic, and animal-health customers.
Industries
Nr. of Employees
small (1-50)
Biovest International
Tampa, Florida, United States, North America
Patents
Method and system for the production of cells and cell products and applications thereof
US-10723993-B2
View DetailsBiomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules
US-10662401-B2
View DetailsBiomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules
US-9902928-B2
View Details
Method and system for the production of cells and cell products and applications thereof
US-10723993-B2
View DetailsBiomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules
US-10662401-B2
View DetailsBiomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules
US-9902928-B2
View DetailsProducts
Personalized cancer vaccine candidate (lead candidate)
A personalized active immunotherapy developed for B-cell non-Hodgkin's lymphoma and evaluated in three clinical trials in collaboration with a national cancer institute; trials indicated increased duration of remission and immune responses that correlate with long-term survival.
Personalized cancer vaccine candidate (lead candidate)
A personalized active immunotherapy developed for B-cell non-Hodgkin's lymphoma and evaluated in three clinical trials in collaboration with a national cancer institute; trials indicated increased duration of remission and immune responses that correlate with long-term survival.
Services
Supply of automated, single-use perfusion bioreactor systems for mammalian cell culture and continuous processing.
Contract manufacturing services for mammalian cell culture and protein production offered to global customers in diagnostics, therapeutics, and animal health.
Supply of automated, single-use perfusion bioreactor systems for mammalian cell culture and continuous processing.
Contract manufacturing services for mammalian cell culture and protein production offered to global customers in diagnostics, therapeutics, and animal health.
Expertise Areas
- Personalized immunotherapy and cancer vaccine development
- Clinical trial execution and clinical collaboration
- Mammalian cell culture and protein manufacturing (CMO)
- Design and commercialization of single-use perfusion bioreactors
Key Technologies
- Personalized active cancer vaccines
- Automated single-use perfusion bioreactors
- Mammalian cell culture systems
- Mammalian cell-derived protein production
News & Updates
Instrument and contract manufacturing offerings were spun off into a dedicated subsidiary in 2016 to focus on bioreactors and manufacturing services.
Three clinical trials in collaboration with a national cancer institute showed increased duration of cancer remission following chemotherapy and immune responses that correlate with long-term survival.
Instrument and contract manufacturing offerings were spun off into a dedicated subsidiary in 2016 to focus on bioreactors and manufacturing services.
Three clinical trials in collaboration with a national cancer institute showed increased duration of cancer remission following chemotherapy and immune responses that correlate with long-term survival.